Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lonsurf in advanced gastric cancer
NCT05508737Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, trifluridine + tipiracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Yonsei University. Started Dec 2022; status: active, not recruiting.
02
Drugs
pembrolizumabtrifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05508737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508737.